**Table1.** Demographics and clinical features of enrolled healthy volunteers and patients with intra-abdominal sepsis.

|  |  |  |
| --- | --- | --- |
|  | **Non-septic** | **Septic patients** |
| **N** | 10 | 9 |
| **Age**, mean (range) ± SD*p* value *vs* septic group | 64.1 (61-66) ± 1.97*p*> 0.05ns | 67.77 (43-83) ± 10.04 |
| **Gender**, N (%)MaleFemale*p* value *vs* septic group | 5 (50%)5 (50%)*p*> 0.05ns | 4 (44.45%)5 (55.55%) |
| **Associated pathologies,** N (%) |
| Diabetes mellitus Type IIArterial hypertensionBrugada’s syndrome | 3 (30%)2 (20%)1 (10%) |  | 3 (33.33%)4 (44.44%)0 |
| **Clinical data***(only for septic patients)* |
| **Initial septic focus,** N (%)*Stomach**Colon**Sigmoid colon**Small intestine**Abdominal, unidentified* |  | 1 (11.11%)5 (55.55%)1 (11.11%)1 (11.11%)1 (11.11%) |
| **Isolated bacteria**, N (%)*Escherichia coli**Streptococcus sp**Prevotella sp**Klebsiella sp**Proteus mirabilis**Candida albicans* |  | 4 (44.44%)4 (44.44%)1 (11.11%)2 (22.22%)1 (11.11%)2 (22.22%) |
| **PCT**mean (range) ng/ml ± SD |  | 28.39 (1.08-100) ± 41 |
| **CRP**mean (range) mg/dl ± SD |  | 37.62 (28.24-49.74) ± 7.17 |
| **CREATININE**mean (range) mg/dl ± SD |  | 1.75 (0.73-3.25) ± 1.02 |
| **ALBUMIN**mean (range) g/dl ± SD |  | 2.34 (1.8-2.9) ± 0.44 |
| **UREA**mean (range) mg/dl ± SD |  | 92.78 (36-188) ± 55.66 |
| **BILIRUBIN**mean (range) mg/dl ± SD |  | 1.58 (0.25-5.31) ± 1.74 |
| **ASPARTATE TRANSAMINASE (AST)**mean (range) U/L ± SD |  | 123.8 (12-858) ± 276.5 |
| **ALANINE TRANSAMINASE (ALT)**mean (range) U/L ± SD |  | 66.22 (10-443) ± 141.5 |
| **ALKALINE PHOSPHATASE**mean (range) U/L ± SD |  | 83.11 (42-176) ± 42.05 |
| **GAMMA GLUTAMYL TRANSFERASE**mean (range) U/L ± SD |  | 53.11 (8-189) ± 63.63 |
| **SOFA** mean (range) ± SD |  |  | 6.44 (3-11) ± 2.79 |
| **APACHEII** mean (range) ± SD |  |  | 17.33 (10-22) ± 4 |
| **Mortality** N (%) |  |  | 1 (11.11%) |

*ns*, no significant difference (*p*> 0.05); SD, standard deviation; Chi-square (𝜒2) test was used, except for age, where a one-way ANOVA test was used.

**Table 2**. Histopathology scoring (average of *n*= 3 animals/group).

|  |  |
| --- | --- |
|  | **Score** |
| **Liver\*** | **Spleen\*\*** | **Lung\*\*\*** |
| C57 BL/6 sham | 2 | 0 | 0 |
| C57 BL/6 CLP 24 h | 5 | 8 | 6 |
| C57 BL/6 CLP 48 h | 4.7 | 8 | 7 |
| C57 BL/6 sham + A438079 | 2.7 | 0 | 0 |
| C57 BL/6 CLP 24 h + A438079 | 7.3 | 11 | 9 |
| C57 BL/6 CLP 48 h + A438079 | 7.3 | n/a | n/a |
| *P2rx7*−/− sham | 3.7 | 0 | 0 |
| *P2rx7*−/− CLP 24 h | 7.3 | 11 | 9 |
| *P2rx7*−/− CLP 48 h | 8 | 11 | 9 |
| *P2rx7*−/− CLP 24 h + rCD14 | 4.3 | 8 | 6 |

\*Liver histological features: steatosis (0: none; 1: <20%; 3: >20%); ballooning (1: occasional; 4: marked); polymorphonuclear cell infiltration (1: none/mild; 3: severe); inflammation (0: none; 2: yes); fibrosis (0: none; 4: yes).

\*\*Spleen histological features: unstructured spleen tissue (0: none; 3: yes); congestion of the white and red pulp (0: none; 3: yes); presence of apoptotic bodies (0: none; 5: yes).

\*\*\*Lung histological features: alveolar congestion (0: none; 3: yes); alveolar thickening (0: none; 3: yes); polymorphonuclear cell infiltration (0: none; 3: yes); fibrosis (0: none; 5: yes).

n/a: not analysed**.**